Collaborations

Collaborations

We seek strategic commercial partnerships to marry the formidable science base of the Institute with the capabilities of commercial partners to add value or derisk technologies for mutual benefit.

Go back to Case Studies

Developing a new therapeutic target in breast cancer

Cancer Research Technology

We are collaborating with the Drug Discovery Unit of Cancer Research Technology in a screening campaign for inhibitors of a novel oncogene discovered at the Institute. We have recently shown that the transcription regulator BCL11A is overexpressed and a potent oncogene in basal-like breast cancer (BLBC). BLBC accounts for 15 per cent of all breast cancer cases and represents a disease subpopulation with high unmet clinical need.

Open Targets

Open Targets logo

For biomedical researchers who need to identify a biological target for a new therapy, the Open Targets platform is a public-private initiative to generate evidence on the validity of therapeutic targets based on genome-scale experiments and analysis. Open Targets is working to create an R&D framework that applies to a wide range of human diseases, and is committed to sharing its data openly with the scientific community.

Visit the Open Targets platform here

CRISPR screen collaboration with Astra Zeneca

Astra Zeneca logo

The Sanger Institute and Astra Zeneca are pulling reources in a collaborative effort which encompasses a suite of individual projects over several years and could see applications in fields as diverse as regenerative medicine, cancer, inflammation or metabolic diseases. The Institute brings its expertise in genome editing and gRNA libraries developed by Dr Kosuke Yusa while Astra Zeneca provides access to its compounds, expertise and cell lines. Findings arising from this common effort will be shared with the worldwide research community for them to build on.

Mouse Colony Management Software

Catalogue of Somatic Mutations in Cancer logo

The Sanger Institute has implemented a licensing step access by commerical parties to its curated catalogue of somatic cancer mutations database, COSMIC (Catalogue of Somatic Mutations in Cancer), in an effort to sustain its development in the context of increasing cancer genomics data. All income generated by this activity, as well as from sponsored database research and development, is used to grow the database as a key public resource.

View the COSMIC platform